Newsfeeds - Spark Newswire

3 minute read

News

Clearside Biomedical Expands XIPERE License Agreement With Arctic Vision To Include Australia, New Zealand, India And ASEAN Countries

Today, 9:36 AM

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced

CLSD

5 minute read

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab

By Shanthi Rexaline

Today, 9:36 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)

ABBV

5 minute read

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical

By Shanthi Rexaline

Today, 9:36 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)

ABSI

3 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 9:36 AM

ACHV

1 minute read

Earnings

Clearside Biomedical: Q2 Earnings Insights

By Benzinga Insights

Today, 9:36 AM

Shares of Clearside Biomedical (NASDAQ:CLSD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 15.38% over the past year to ($0.11), which beat the estimate of ($0.12).

CLSD

1 minute read

Clearside Biomedical Q2 EPS $(0.11) Beats $(0.12) Estimate, Sales $800.00K Beat $690.00K Estimate

By Benzinga Newsdesk

Today, 9:36 AM

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 15.38 percent increase over losses of $(0.13) per share

CLSD

6 minute read

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts

By Shanthi Rexaline

Today, 9:36 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)

ACET

10 minute read

Earnings Scheduled For August 10, 2021

By Benzinga Insights

Today, 9:36 AM

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.

ABST

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 9:36 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For July 29, 2021

By Benzinga Insights

Today, 9:36 AM

Upgrades

ACDVF